Organon & Co.

Healthcare · Drug Manufacturers - General

Overall research band Weak

Quality Very weak

Valuation Weak

Balance sheet Very weak

Market confirmation Above average

One-minute company read

What this report can tell you now

What the company does

Organon & Co. is a global pharmaceutical company focused on developing and delivering a broad range of prescription therapies. Its main products include women's health treatments such as birth control and fertility therapies (notably Nexplanon/Implanon), a portfolio of biosimilars for immune and cancer conditions (Brenzys, Renflexis, Hadlima, Ontruzant, Aybintio), cardiovascular medications (including Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor, Cozaar, Hyzaar), respiratory therapies for asthma and allergies (Singulair, Dulera, Zenhale, Asmanex, Nasonex, Clarinex, Aerius), dermatological treatments (Diprosone, Elocon), bone health (Fosamax), non-narcotic pain relief (Arcoxia, Diprospan, Celestone), and products for benign prostatic hyperplasia and hair loss (Proscar, Propecia). Organon distributes its products primarily to pharmaceutical wholesalers, retailers, medical facilities, government agencies, and managed healthcare organizations, generating revenue through the sale of these therapies. The company was established in 2020 and is headquartered in Jersey City, New Jersey.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC10.6%Model input; read with the evidence status and period context.

Operating margin19.2%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years-0.4%Model input; read with the evidence status and period context.

FCF margin10.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.